Alefacept valuable against psoriatic arthritis

New Orleans - Results from a single-center pilot study indicatethat I.V. alefacept (Amevive), the human LFA3-IgG1 fusion protein, may safelyand effectively improve the skin and joint manifestations of psoriatic arthritis,researchers from the Academic Medical Center, University of Amsterdam, TheNetherlands, reported at the annual meeting of the American Academy of Dermatology.

Related Videos

Related Content

Advertisement

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article

ReV Up Your Vitiligo Treatment Strategies

Podcast

Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Article

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article

Related Content

Advertisement

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article

ReV Up Your Vitiligo Treatment Strategies

Podcast

Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Article

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article